checkAd

    DGAP-News  701  0 Kommentare ImevaX secures EUR 7.5 million in Series A Financing to develop highly specific vaccine against Helicobacter pylori infections


    DGAP-News: ImevaX GmbH / Key word(s): Financing
    ImevaX secures EUR 7.5 million in Series A Financing to develop highly
    specific vaccine against Helicobacter pylori infections

    28.10.2014 / 09:00

    ---------------------------------------------------------------------

    Press Release

    ImevaX secures EUR 7.5 million in Series A Financing to develop highly
    specific vaccine against Helicobacter pylori infections

    Munich (Germany), October 28, 2014: ImevaX GmbH, a specialist in vaccines
    against pathogens of chronic infectious diseases, announces today the
    completion of a EUR 7.5 million Series A financing round. The round was led
    by Wellington Partners. Co-lead investors were BioMedPartners with their
    BioMedInvest-II LP fund, EMBL Ventures and Santo Venture Capital. ImevaX is
    a 2014 spin-out from the Technische Universität München (TUM) and has been
    recently awarded a EUR 5.9 million financing from the GO-Bio Phase II
    program of the Federal Ministry of Education and Research (BMBF).

    The funds will be used to advance lead candidate IMX 101 through clinical
    trials before partnering. IMX 101 is a highly specific vaccine against
    Helicobacter pylori (H. pylori). Chronic infections of the stomach with H.
    pylori are the most common bacterial infections worldwide and lead to
    gastritis, stomach ulcers and potentially stomach cancer. Due to the high
    global infection rate and the decreasing efficacy of existing antibiotics
    against H. pylori plus the poor safety profile of these treatments, there
    exists a high medical need and a significant commercial interest in a H.
    pylori vaccine.

    "In light of the pandemic nature of H. pylori infections and the high
    medical need, it is essential to develop novel treatment strategies for
    this chronic disease," said Professor Erich Schlick, General Partner at
    Wellington Partners and member of the Advisory Board of ImevaX GmbH. "This
    is why we are strongly committed to the ImevaX vaccine approach."

    Dr Markus Hosang of BiomedPartners, Dr Jan Adams of EMBL Ventures and Dr
    Ulrich Granzer of Granzer Regulatory Consulting have also joined the
    Advisory Board of ImevaX.

    Volker Wedershoven, Chief Executive Officer of ImevaX GmbH since September
    1, 2014 commented: "We are delighted to receive this strong support from
    such experienced life sciences investors; their knowledge and experience
    will be invaluable to the development of ImevaX and our pipeline of
    infectious diseases treatments. This round of financing will support the
    development of IMX 101 into the clinic and potentially into partnering
    Seite 1 von 3


    EQS Group AG
    0 Follower
    Autor folgen
    Verfasst von EQS Group AG
    DGAP-News ImevaX secures EUR 7.5 million in Series A Financing to develop highly specific vaccine against Helicobacter pylori infections DGAP-News: ImevaX GmbH / Key word(s): Financing ImevaX secures EUR 7.5 million in Series A Financing to develop highly specific vaccine against Helicobacter pylori infections 28.10.2014 / 09:00 …